Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
OnCusp Therapeutics logo — We Bring Oncology Innovation to Life

OnCusp Therapeutics

We Bring Oncology Innovation to Life

Founded 2021 United States New York, United States 28 employees Series A Total: $125.00M Biotechnology, Health Care +1

General Information

Company Name OnCusp Therapeutics
Founded Year 2021
Location United States New York, United States
Employees 28
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series A
Business Model B2B
Revenue Model Licensing, Performance Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with OnCusp Therapeutics. To contact OnCusp Therapeutics, visit oncusptx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OnCusp Therapeutics compare?

A PDF of OnCusp Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last six months. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OnCusp Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last year of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OnCusp Therapeutics

OnCusp Therapeutics is a promising player in the biopharmaceutical industry, founded in 2021 with headquarters in the United States. Their mission, elegantly encapsulated in their slogan, "We Bring Oncology Innovation to Life," reflects a dedication to evolving preclinical discoveries into validated cancer treatments.

The company thrives under the leadership of co-founders Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu. OnCusp has assembled a team with deep experience in biotech startups and global partnership creation, paving the way for strategic advancement in oncology assets.

Recently, OnCusp secured a significant $100.00M Series A investment on 01 January 2024, attracting a diverse group of prominent investors, including Novo Holdings, Blackbird Ventures, and F-Prime Capital, among others. This underscores investor confidence and positions OnCusp for impactful growth and innovation in the highly competitive biotechnology, health care, and pharmaceutical sectors.

Taxonomy: biopharmaceutical, oncology, cancer treatments, preclinical innovation, clinical validation, drug development, biotech startups, global partnerships, oncology assets, innovation acceleration, research asset transformation, oncology medication innovation

Services & Products

Development of Oncology Treatments
Clinical R&D
Partnership and Collaboration
Business Development

Target Customers

Cancer Patients Healthcare Providers Pharmaceutical Companies Research Institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $100.00M 10
Novo Holdings Blackbird Ventures F-Prime Capital
Novo Holdings, Blackbird Ventures +8
01 Jan 2024
Seed $25.00M 3
BioTrack Capital
BioTrack Capital, HongShan +1
01 Apr 2021

OnCusp Therapeutics Alternatives & Competitors

View All Alternatives
OnCusp Therapeutics vs
Prelude Therapeutics
Prelude Therapeutics United States

Precision Oncology, Redefined.

Post-IPO Equity
126 employees
Biopharma, Biotechnology
Compare OnCusp Therapeutics vs Prelude Therapeutics
OnCusp Therapeutics vs
Pannex Therapeutics Inc.
Pannex Therapeutics Inc. United States

We are the Pannexin people.

Seed
4 employees
Biotechnology, Pharmaceutical
OnCusp Therapeutics vs
NBE-Therapeutics AG
NBE-Therapeutics AG Switzerland

Next generation antibody drug conjugates

Series C
48 employees
Biotechnology, Health Care
Also compare with: OnCusp Therapeutics vs Bolt Biotherapeutics, Inc. Bolt Biotherapeutics, Inc. View all alternatives

FAQ About OnCusp Therapeutics

We Bring Oncology Innovation to Life
OnCusp Therapeutics was founded in 2021.
OnCusp Therapeutics is headquartered in New York, United States.
OnCusp Therapeutics operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceutical, oncology, cancer treatments and preclinical innovation. Its customers include Cancer Patients, Healthcare Providers and Pharmaceutical Companies.
OnCusp Therapeutics has a B2B business model. Its revenue comes from Licensing, Performance Based and Product Sales.
OnCusp Therapeutics has approximately 28 employees.
OnCusp Therapeutics has completed 2 funding rounds, raising a total of $125.00M. The latest funding stage is Series A.
OnCusp Therapeutics offers: Development of Oncology Treatments, Clinical R&D, Partnership and Collaboration, Business Development.
Top alternatives and competitors to OnCusp Therapeutics include Prelude Therapeutics, Pannex Therapeutics Inc., NBE-Therapeutics AG, Rexahn Pharmaceuticals, KeifeRx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OnCusp Therapeutics and Prelude Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OnCusp Therapeutics, https://bouncewatch.com/company/oncusp-therapeutics, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes